Evaluating the use of dose-sparing vaccination strategies for Monkeypox

Abstract

The spring-summer 2022 monkeypox outbreak had over 50,000 cases globally, most of them in gay, bisexual, and other men who have sex with men (MSM). In response to vaccine shortages, several countries implemented dose-sparing vaccination strategies, stretching a full-dose vaccine vial in up to 5 fractional-dose vaccines. Recent studies have found mixed results regarding the effectiveness of the monkeypox vaccine, raising the question of the utility of dose-sparing strategies. We used an age- and risk-stratified mathematical model of an urban MSM population in the United States with approximately 12% high-risk MSM to evaluate potential benefits from implementing dose-sparing vaccination strategies in which a full dose is divided in 3.5 fractional-doses. We found that results strongly depend on the fractional-dose vaccine effectiveness (VE) and vaccine supply. With very limited vaccine available, enough to protect with a full-dose approximately one-third of the high-risk population, dose-sparing strategies are more beneficial provided that fractional-dose preserved at least 40% of full dose effectiveness (34% absolute VE), projecting 13% (34% VE) to 70% (68% absolute VE) fewer infections than full-dose strategies. In contrast, if vaccine supply is enough to cover the majority of the high-risk population, dose-sparing strategies can be outperformed by full-dose strategies. Scenarios in which fractional-dosing was 34% efficacious result in almost three times more infections than full-dosing. Our analysis suggests that when monkeypox vaccine supply is limited and fractional-dose vaccination retains moderate effectiveness, there are meaningful health benefits from providing a smaller dose to a larger number of people in the high-risk population.

Nationwide analysis of the impact of COVID-19 in patients with a cardiovascular, oncological or chronic pulmonary disease in the context of an Eastern European country with a low vaccination rate, Bulgaria: March 2020–April 2022

“…This tool provides evidence-based support and streamlines the entire decision-making process, providing the vaccinator with the most relevant and objective recommendation for the patient in less than a minute. The project received full support from the Bulgarian Medical Association, which can be accessed via its website free of charge 25. Unlike other similar and successful digital solutions,26 our platform targets healthcare professionals.…”